Don't Treat PRAAMS' "AI Co-Investor 5.0" as an Edge You Can Own

On the surface, "AI Co-Investor 5.0" sounds like the thing every self-directed investor has been waiting for: software that does your research, weighs your risks, and builds your portfolio — a second brain sitting next to yours. PRAAMS, an Andorran fintech, launched the latest version of that platform today. But one fact deserves to come before any enthusiasm: PRAAMS is a private company, so you cannot buy a share of this launch. The only question worth your attention is whether the tool is actually worth using.

PRAAMS itself is a young, self-funded operation. It was founded in Andorra in 2022 and is run by veterans who say they spent two decades at brokers, asset managers, and investment banks, with roughly $1.5 trillion of assets under their risk oversight. It has been pushing this platform out in stages — institutional "wealthtech" tools in 2024, an investing portal with EODHD's data service in 2025, and now version 5.0 — so this week's announcement extends an existing product line rather than inventing a company from nothing.

What 5.0 actually does

The pitch is that 5.0 removes the patchwork of separate tools a professional normally juggles. It claims a single workflow that moves from researching a company, to screening the market, to constructing a portfolio, to monitoring it afterward. The research mode analyzes a company and its peers, pulls in news, filings, earnings-call transcripts, and sector trends, and attributes every claim back to a source you can drill into. The build-out covers more than 400,000 instruments worldwide — stocks, bonds, ETFs, funds, crypto, and currency — with a knowledge base the company says refreshes every minute.

At the retail end, you don't get the full institutional engine. Consumers receive a scaled-down version, "AI Co-Investor 5.0 Light," delivered through PRAAMS' personal apps. Premium access runs about €270 a year, and PRAAMS donates 1% of payments to the Red Cross.

The gap between the trailer and the edge

Here is where the marketing deserves the same skepticism you would apply to a stock that is up 40% on a narrative. The flagship number — portfolio optimization across a theoretical space of 17 trillion configurations — is impressive-sounding, but it measures the size of the area searched, not the quality of the answer. An optimizer that searches far more combinations than you could by hand is genuinely useful; it will beat an amateur with a spreadsheet. But it optimizes within the constraints you hand it, using public data anyone can pull. Feed it your risk limits and the same pricing and financials the rest of the market sees, and it returns the portfolio consistent with those inputs. It can make you faster and more rigorous; it cannot manufacture an information edge that no one else has, because the inputs it reasons over are the same ones available to everyone.

That is not an argument that the tool is worthless — it is an argument about what the tool is for. The genuinely useful thing here is honesty about the boundary, and PRAAMS supplies it in its own fine print: the company states plainly that it provides no individual investment advice and is not a licensed investment adviser. Read that against the "co-investor" branding and the product resolves into what the file name really says — decision support, not a decision-maker. The judgment still rests with you.

The one twist worth remembering is that the company's own educational material lectures users about the behavioral traps of investing — anchoring on your purchase price, mistaking a hot idea for a durable one, letting a broker's questionnaire dictate your risk appetite. Those are real and useful warnings. But a tool that optimizes around constraints you input is itself a framing device: if your priors are wrong, the "co-investor" faithfully reproduces them, only faster and with prettier charts. It can police your biases; it cannot decide for you which signal deserves weight.

For the retail investor, the honest conclusion is a modest one. A research tool that checks its sources and runs your numbers consistently is a real upgrade over a scattering of free screeners — it can save hours and catch your arithmetic. What it cannot do is hand you the thing that actually separates durable investors from the crowd: judgment about which fact moves the risk/reward and whether the market has priced it in. That part is not a feature you can subscribe to. So treat this launch as a useful research aid worth evaluating on its own terms — and not as an investment opportunity, because it is not one you can own.